Hereditary angioedema (HAE) is a rare genetic condition characterized by recurrent and unpredictable swelling episodes. For individuals suffering from this debilitating disorder, Takhzyro (lanadelumab-flyo) has emerged as a beacon of hope. This medication aims to reduce the frequency of HAE attacks in adults and certain pediatric populations. However, like all pharmaceuticals, Takhzyro is not without